Mineralys has been on the radar for some biotech investors. Read more about MLYS' hypertension treatment, upcoming trial ...

Medicare Part D provides coverage for Entresto. Learn more about Medicare drug coverage and the costs of Entresto.

A new study from the PARADIGM-HF and PARAGON-HF clinical trials found that sacubitril/valsartan significantly reduced the ...

Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company ...

The findings presented at ESC showed that the use of sacubitril/valsartan (Sac/Val) on top of existing recommended HF therapies prompted a greater N-terminal pro-brain natriuretic peptide ...

Highlighted text has been updated as of August 30, 2024. The PARAGON-HF trial failed to show that sacubitril/valsartan reduced adverse events among patients with HFpEF. Patients with HFpEF were ...

Most of the world’s biggest news website saw strong growth in July in what was a bumper month for news. July saw an assassination attempt against Donald Trump, Joe Biden announcing he would not ...

1 Xi’an International Medical Center Hospital Affiliated to Northwest University, Xi’an, China 2 Shaanxi Provincial People's Hospital, Xi’an, China Purpose: Sacubitril/valsartan is extensively used in ...